Susan Shiff
Vermögen: 18 969 $ am 31.05.2026
Vermögen: 18 969 $ am 31.05.2026
Susan Patricia Shiff currently works at Huma.ai, Inc., as President, Chief Executive Officer & Director from 2024, Merck Global Health Innovation Fund LLC, as Director, Synthace Ltd., as Director from 2018, Tvardi Therapeutics, Inc., as Independent Director from 2025, and New Jersey Symphony Orchestra, as Trustee.
Dr. Shiff also formerly worked at CARA Therapeutics, Inc., as Independent Director, Merck & Co., Inc., as Senior Vice President from 2014 to 2021, Pfizer Inc., as Vice President, Teva Pharmaceutics, as Vice President-Global Health Economics, and Ontada LLC, as President from 2021 to 2023.
Dr. Shiff received her doctorate degree from the University of California, Los Angeles and Masters Business Admin degree from Cornell University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,06 % | 09.06.2026 | 5.612 ( 0,06 % ) | 18 969 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
Synthace Ltd.
Synthace Ltd. Packaged SoftwareTechnology Services Develops life sciences R&D cloud platform | Direktor/Vorstandsmitglied | 05.06.2018 |
Merck Global Health Innovation Fund LLC
Merck Global Health Innovation Fund LLC Investment ManagersFinance Acts as Venture Capital Fund | Direktor/Vorstandsmitglied | - |
New Jersey Symphony Orchestra
New Jersey Symphony Orchestra Media ConglomeratesConsumer Services Operates as non profit performing arts organization | Direktor/Vorstandsmitglied | - |
Huma.AI, Inc.
Huma.AI, Inc. Packaged SoftwareTechnology Services Develops life sciences AI software platform for medical affairs organization | Vorstandsvorsitzender | 01.07.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
Ontada
Ontada Medical/Nursing ServicesHealth Services Provides oncology treatment services | Präsident | 01.07.2023 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.03.2021 |
| PFIZER INC. | Corporate Officer/Principal | - |
Teva Pharmaceutics | Corporate Officer/Principal | - |
| CARA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
CARA Therapeutics, Inc.
CARA Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed | Health Technology |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New Jersey Symphony Orchestra
New Jersey Symphony Orchestra Media ConglomeratesConsumer Services Operates as non profit performing arts organization | Consumer Services |
Teva Pharmaceutics | |
Merck Global Health Innovation Fund LLC
Merck Global Health Innovation Fund LLC Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Synthace Ltd.
Synthace Ltd. Packaged SoftwareTechnology Services Develops life sciences R&D cloud platform | Technology Services |
Huma.AI, Inc.
Huma.AI, Inc. Packaged SoftwareTechnology Services Develops life sciences AI software platform for medical affairs organization | Technology Services |
Ontada
Ontada Medical/Nursing ServicesHealth Services Provides oncology treatment services | Health Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen